FDA

The Food and Drug Administration (FDA) is a US federal agency responsible for protecting public health by regulating food, drugs, medical devices, cosmetics, and other consumer products. It operates under the authority of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA's regulatory framework includes pre-market approval processes, such as 510(k) clearance and Premarket Approval (PMA) for high-risk devices, as well as post-market surveillance. For enterprises, FDA compliance is not just a legal requirement but a strategic necessity for accessing the world's largest healthcare market. The agency's standards often exceed international norms, particularly in the areas of clinical evidence and manufacturing quality control (cGMP).

FDA compliance in enterprise risk management (ERM) involves three critical stages. First, Design Risk Assessment: Companies must identify hazards and estimate risks associated with device design and intended use, adhering to ISO 14971 standards. Second, Risk Control: This involves implementing design changes, manufacturing controls, and labeling requirements to mitigate identified risks to an acceptable level. Third, Post-Market Surveillance: Companies must be closely monitoring the real-world performance of their products, reporting adverse events under 21 CFR Part 803, and conducting periodic benefit-risk evaluations. A key example is the 2018 iCGM standard, which requires continuous monitoring of device accuracy in real-use scenarios, necessitating a robust data-gathering and reporting infrastructure within the company's quality management system (QMS).

Taiwan enterprises typically face three primary challenges: regulatory interpretation gaps, clinical data requirements, and supply chain-related compliance. Many companies struggle with the granularity of FDA documentation compared to local standards. To overcome this, enterprises should adopt ISO 14121 as a baseline and hire US-specialized regulatory consultants. Second, the demand for robust clinical data for devices like iCGM can be overwhelming; companies should be closely monitoring FDA's evolving guidance and investing in high-quality clinical study designs. Third, supply chain-related risks can be mitigated by implementing a rigorous supplier qualification program. We recommend a phased approach: starting with a gap analysis, followed by a 90-day implementation plan, and finally a pre-submission consultation with the FDA to de-risk the application process.

Winners Consulting Services Co., Ltd. specializes in FDA compliance for Taiwan enterprises, delivering compliant management systems within 90 days. We provide comprehensive support including product classification, risk assessment frameworks, and pre-submission strategies. Our expertise in iCGM and digital health regulations ensures your company stays ahead of regulatory changes. Free consultation: https://winners.com.tw/contact